Hua Medicine Reports Strong Results For Early Diabetes Drug Trial
3/20/2014 12:59:37 PM
by Richard Daverman, PhD
March 20, 2014 -- Hua Medicine of Shanghai announced it will start a Phase Ib trial of its glucokinase activator (GKA) treatment for type 2 diabetes. In the Phase Ia trial, HMS5552 produced positive results in healthy volunteers. Because of the excellent early results, Hua thinks HMS5552 may be a best-in-class candidate. The Phase Ib trial will test the drug in type 2 diabetics. Hua, which in-licensed the second generation GKA drug from Roche, holds global rights to HMS5552. More details....
Stock Symbol: (SIX: ROG)
Help employers find you! Check out all the jobs and post your resume.
comments powered by